Rosemarie Lajara, MD
Endocrinology, Diabetes & Metabolism · Plano, TXNPI 1780862102
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $842,626 of the $1,203,461 with a category attached, or 70.0%. 47 manufacturers reported payments, led by Lilly USA, LLC at 34.3% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,331 payments — averaging $516.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$413K
- Novo Nordisk$236K
- Abbott$216K
- Boehringer Ingelheim$97K
- AstraZeneca$55K
- Sanofi-aventis U.S. LLC$54K
- plus $132K from 41 others
What the payments were for
- Consulting fees$143,42312%
- Speaking & faculty fees$842,62670%
- Travel & lodging$175,25615%
- Food & beverage$42,0193%
- Education$780%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$253,922
- FREESTYLE LIBRE 3$188,029
- TRULICITY$111,430
- Ozempic$89,953
- RYBELSUS$81,123
- MOUNJARO$64,393
- FARXIGA$50,229
- HUMULIN$32,950
- Victoza$32,695
- TWIIST$30,596
- SOLIQUA 100/33$21,757
- V-GO$19,777
- Omnipod$17,629
- Korlym$14,290
- TOUJEO$11,631
- FreeStyle Libre$10,629
- TZIELD$9,464
- Tresiba$5,618
- AFREZZA$4,776
- Vascepa$4,288
How this compares
$1,203,461 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $234,418 |
| MounjaroTirzepatide | 92 | $148,829 |
| JardianceEmpagliflozin | 82 | $120,196 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $62,384 |
| TrulicityDulaglutide | 45 | $55,081 |
| JanuviaSitagliptin Phosphate | 31 | $44,655 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $44,479 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $39,294 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $33,890 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $31,242 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $27,480 |
| ProliaDenosumab | 13 | $23,127 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $22,487 |
| FarxigaDapagliflozin Propanediol | 15 | $20,703 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $16,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $236,026 | $241,548170 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $412,511 | $211,350159 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $97,163 | $181,283123 claims |
| MerckJanuvia, Janumet Xr | $303 | $67,14248 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $54,348 | $27,48029 claims |
| AmgenProlia | $168 | $23,12713 claims |
| AstraZenecaFarxiga | $54,872 | $20,70315 claims |
| AbbVieSynthroid | $216 | $3,20935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Plano
- Mitchell SorsbyPlano$945K
- Heidi SheaPlano$186K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.